NASDAQ: RVPHReviva Pharmaceuticals Holdings Inc Stock
$0.88+0.06 (+7.32%)
Updated May 6, 2026
RVPH Price
$0.88
Fair Value Price
N/A
Market Cap
$11.27M
52 Week Low
$0.59
52 Week High
$23.20
P/E
-0.16x
P/B
1.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$19.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.84
Operating Cash Flow
-$25M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RVPH Overview
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RVPH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RVPH news, forecast changes, insider trades & much more!
RVPH News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RVPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RVPH is good value based on its book value relative to its share price (1.3x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RVPH due diligence checks available for Premium users.
Valuation
RVPH fair value
Fair Value of RVPH stock based on Discounted Cash Flow (DCF)
Price
$0.88
Fair Value
$7.85
Undervalued by
88.80%
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RVPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
17.24x
Market
20.8x
RVPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.3x
Industry
5.11x
RVPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RVPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
RVPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.9M
Liabilities
$7.3M
Debt to equity
0.84
RVPH's short-term assets ($15.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RVPH's short-term assets ($15.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RVPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RVPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.8M
Investing
$0.0
Financing
$7.1M
RVPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RVPH vs Biotech Stocks
Reviva Pharmaceuticals Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.